Article Text

Download PDFPDF
The B cell in systemic lupus erythaematosus: a rational target for more effective therapy
  1. C B Driver,
  2. M Ishimori,
  3. M H Weisman
  1. Cedars-Sinai Medical Center, Los Angeles, California, USA
  1. Dr M H Weisman, Division of Rheumatology, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, California 90048, USA; weisman{at}


Current treatment options for systemic lupus erythaematosus (SLE) are diverse and poorly defined, and aggressive therapy can be associated with serious toxicity and tolerability issues. There is, therefore, a need for new and improved treatments to be studied thoroughly in well-designed controlled trials. B Cell dysfunction has emerged as a key pathophysiological component of SLE and is a prime target for the development of new agents for a wide range of lupus severity, including advanced disease. Although many current drugs appear to modify B cell function, the advent of new, targeted therapies offers the hope of improved efficacy and a better long-term tolerability profile.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding: Support for the preparation of this manuscript was provided by Genentech, Inc.

  • Competing interests: None declared.